first trust dsip portfolio FTREX Product Page First Trust

V.et al (2021)

They are compounded by licensed 503A pharmacies with physician oversight and sterile quality standards, prioritizing real therapeutic outcomes over cheaper, unregulated research-grade products

The following resources are also available to read on WADAs website: The full 2025 Prohibited List The WADA 2025 Summary of Major Modifications and Explanatory Notes The 2025 Monitoring Program which includes substances not currently on the List but are being monitored by WADA for potential patterns of misuse in sport.

Anyone with persistent shoulder problems should obtain proper imaging and diagnosis before assuming peptide therapy will resolve their specific condition

Bottom line: even if the FDA eventually recommends that certain peptides can be compounded under Section 503A, many stakeholders could still be blocked by the requirement to source pharmaceutical-grade API from an FDA-registered establishment with a Certificate of Analysis and by FDAs demonstrated willingness to police marketing claims around compounded drugs

Peptide therapies vary in price depending on formulation and provider but are increasingly accessible through concierge medicine and functional health clinics